LT3849970T - Kristalinis (r)-5-karbamoilpiridin-3-il-2-metil-4-(3-(trifluormetoksi)benzil) piperazin-1-karboksilatas, jo kompozicijos ir panaudojimo būdai - Google Patents

Kristalinis (r)-5-karbamoilpiridin-3-il-2-metil-4-(3-(trifluormetoksi)benzil) piperazin-1-karboksilatas, jo kompozicijos ir panaudojimo būdai

Info

Publication number
LT3849970T
LT3849970T LTEPPCT/US2019/050771T LTUS2019050771T LT3849970T LT 3849970 T LT3849970 T LT 3849970T LT US2019050771 T LTUS2019050771 T LT US2019050771T LT 3849970 T LT3849970 T LT 3849970T
Authority
LT
Lithuania
Prior art keywords
carbamoylpyridin
trifluoromethoxy
piperazine
carboxylate
benzyl
Prior art date
Application number
LTEPPCT/US2019/050771T
Other languages
English (en)
Lithuanian (lt)
Inventor
Lianfeng Huang
Nancy TSOU
Nicole White
Jun Xu
Qun Zhang
Original Assignee
Celgene Corporation
Lundbeck La Jolla Research Center, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corporation, Lundbeck La Jolla Research Center, Inc. filed Critical Celgene Corporation
Publication of LT3849970T publication Critical patent/LT3849970T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
LTEPPCT/US2019/050771T 2018-09-13 2019-09-12 Kristalinis (r)-5-karbamoilpiridin-3-il-2-metil-4-(3-(trifluormetoksi)benzil) piperazin-1-karboksilatas, jo kompozicijos ir panaudojimo būdai LT3849970T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731014P 2018-09-13 2018-09-13
PCT/US2019/050771 WO2020056105A1 (en) 2018-09-13 2019-09-12 Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
LT3849970T true LT3849970T (lt) 2024-10-10

Family

ID=68069873

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/050771T LT3849970T (lt) 2018-09-13 2019-09-12 Kristalinis (r)-5-karbamoilpiridin-3-il-2-metil-4-(3-(trifluormetoksi)benzil) piperazin-1-karboksilatas, jo kompozicijos ir panaudojimo būdai
LTEP24185102.1T LT4434583T (lt) 2018-09-13 2019-09-12 Kristalinis (r)-5-karbamoilpiridin-3-il-2-metil-4-(3-(trifluormetoksi)benzil)piperazin-1-karboksilatas, kompozicijos ir jų panaudojimo būdai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP24185102.1T LT4434583T (lt) 2018-09-13 2019-09-12 Kristalinis (r)-5-karbamoilpiridin-3-il-2-metil-4-(3-(trifluormetoksi)benzil)piperazin-1-karboksilatas, kompozicijos ir jų panaudojimo būdai

Country Status (28)

Country Link
US (4) US11053199B2 (cg-RX-API-DMAC7.html)
EP (3) EP3849970B1 (cg-RX-API-DMAC7.html)
JP (1) JP7405840B2 (cg-RX-API-DMAC7.html)
KR (1) KR102844245B1 (cg-RX-API-DMAC7.html)
CN (3) CN118561814A (cg-RX-API-DMAC7.html)
AU (1) AU2019337623B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004340A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112200A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000596A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003295A2 (cg-RX-API-DMAC7.html)
DK (2) DK4434583T5 (cg-RX-API-DMAC7.html)
EA (1) EA202190511A1 (cg-RX-API-DMAC7.html)
ES (2) ES2993173T3 (cg-RX-API-DMAC7.html)
FI (2) FI3849970T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20260757T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068147T2 (cg-RX-API-DMAC7.html)
IL (1) IL281276B2 (cg-RX-API-DMAC7.html)
LT (2) LT3849970T (cg-RX-API-DMAC7.html)
MA (2) MA71839B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021002923A (cg-RX-API-DMAC7.html)
MY (2) MY208901A (cg-RX-API-DMAC7.html)
PL (2) PL3849970T3 (cg-RX-API-DMAC7.html)
PT (2) PT4434583T (cg-RX-API-DMAC7.html)
RS (2) RS68181B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102143RA (cg-RX-API-DMAC7.html)
SI (1) SI3849970T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202600252T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020056105A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2993173T3 (en) 2018-09-13 2024-12-23 Celgene Corp Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007010076A (es) * 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
EP3099332A4 (en) * 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
PT3595665T (pt) * 2017-03-13 2024-11-21 Lundbeck La Jolla Research Center Inc Inibidores duplos de magl e faah
ES2993173T3 (en) 2018-09-13 2024-12-23 Celgene Corp Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Also Published As

Publication number Publication date
KR20210057789A (ko) 2021-05-21
US11053199B2 (en) 2021-07-06
MA53607A (fr) 2021-12-22
EP4434583A2 (en) 2024-09-25
JP2022500441A (ja) 2022-01-04
HUE068147T2 (hu) 2024-12-28
KR102844245B1 (ko) 2025-08-11
ES2993173T3 (en) 2024-12-23
WO2020056105A9 (en) 2020-07-09
MX2021002923A (es) 2021-09-08
FI4434583T3 (fi) 2026-05-15
HRP20260757T1 (hr) 2026-08-14
EP4434583B1 (en) 2026-04-01
PL3849970T3 (pl) 2025-01-07
AU2019337623A1 (en) 2021-05-13
US20210363105A1 (en) 2021-11-25
RS68181B1 (sr) 2026-06-30
US20260062384A1 (en) 2026-03-05
US11680046B2 (en) 2023-06-20
PL4434583T3 (pl) 2026-07-20
DK4434583T5 (da) 2026-07-06
EP4434583A3 (en) 2024-11-20
SG11202102143RA (en) 2021-04-29
MY208901A (en) 2025-06-09
EP3849970A1 (en) 2021-07-21
CA3112200A1 (en) 2020-03-19
AU2019337623B2 (en) 2024-12-05
IL281276A (en) 2021-04-29
SMT202400369T1 (it) 2024-11-15
EP4768081A2 (en) 2026-07-01
EA202190511A1 (ru) 2021-07-05
EP3849970B1 (en) 2024-07-03
SMT202600252T1 (it) 2026-07-16
PT3849970T (pt) 2024-09-25
SI3849970T1 (sl) 2024-11-29
IL281276B2 (en) 2025-01-01
IL281276B1 (en) 2024-09-01
CN113227069B (zh) 2024-11-05
MY210363A (en) 2025-09-13
CL2021000596A1 (es) 2021-07-30
LT4434583T (lt) 2026-06-25
DK4434583T3 (da) 2026-06-15
PT4434583T (pt) 2026-06-11
US12410133B2 (en) 2025-09-09
US20200095201A1 (en) 2020-03-26
WO2020056105A1 (en) 2020-03-19
MA53607B1 (fr) 2025-05-30
RS65967B1 (sr) 2024-10-31
HRP20241294T1 (hr) 2024-12-06
JP7405840B2 (ja) 2023-12-26
CN118530218A (zh) 2024-08-23
FI3849970T3 (fi) 2024-09-20
CO2021003295A2 (es) 2021-07-30
ES3072981T3 (en) 2026-07-07
US20230382861A1 (en) 2023-11-30
MA71839B1 (fr) 2026-05-26
CN113227069A (zh) 2021-08-06
BR112021004340A2 (pt) 2021-05-25
CN118561814A (zh) 2024-08-30
DK3849970T3 (da) 2024-09-30

Similar Documents

Publication Publication Date Title
IL288278A (en) Alternative 1-oxo-isoindolin-5-carboxamide compounds, compounds thereof, and methods of treatment therewith
IL285302A (en) Compounds, preparations and methods
RS67170B1 (sr) Heterociklična jedinjenja i njihova upotreba
IL274488B1 (en) Crystal forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
EP3846639A4 (en) ANTIPATHOGENIC COMPOSITIONS AND METHODS THEREOF
SG11202105730TA (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
ZA202205727B (en) Substituted-isoxazoline-containing aromatic compound, preparation method therefor, herbicidal composition and use thereof
EP3697791A4 (en) HETEROCYCLIC COMPOUNDS, COMPOSITIONS INCLUDING A HETEROCYCLIC COMPOUND, AND METHODS OF USING THEREOF
SG11202011041YA (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
IL277786A (en) AAV preparations, methods of preparation and methods of use
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
IL287120A (en) Compounds, preparations and methods
IL286164A (en) -(2-bromo-4-alkynyl-6-alkoxyphenyl)-3-pyrroline-2-ones and their use as herbicides
IL281276A (en) Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof
ZA202108764B (en) Herbicidal composition
HK40042752A (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
HK40042751A (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
IL286325A (en) 3-(2-Alkoxy-6-alkyl-4-propynylphenyl)-3-pyrroline-2-ones are specifically converted and their use as herbicides
HK40062036A (en) Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4-dihydropyrimidin-2-one, and methods of use thereof
HK40068676A (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
HK40072378A (en) Compounds, compositions, and methods of use
HK40038575A (en) Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
GB201810326D0 (en) Crystalline form of sacubitril, its preparation and use
HK1259646A1 (en) Rapaglutins, novel inhibitors of glut and use thereof